Document is current
Any future updates will be listed below
-
Authors
Ree, Anne Hansen https://orcid.org/0000-0002-8264-3223
Bousquet, Paula A.
Visnovska, Tina
Lüders, Torben
Geisler, Benjamin P.
Wang, Shixiong
Bordin, Diana L.
Nilsen, Hilde L.
Hamre, Hanne M.
Kersten, Christian
Hofsli, Eva
Guren, Marianne G.
Sorbye, Halfdan https://orcid.org/0000-0002-7132-6214
Berg, Jens P.
Flatmark, Kjersti
Meltzer, Sebastian https://orcid.org/0000-0001-6640-3927
- License Information
-
More Information
Article History
Received: 13 August 2025
Revised: 7 January 2026
Accepted: 6 February 2026
First Online: 23 February 2026
Competing interests
: AHR reports research support (on behalf of Akershus University Hospital) and a personal honorarium from Bristol-Myers Squibb and has served on scientific advisory boards of MSD and Takeda. HMH reports personal honoraria from Bristol-Myers Squibb, Bayer and Roche and has served on scientific advisory boards of Incyte, Eisai, Astellas and AstraZeneca. EH reports personal honoraria from Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo and Takeda. HS reports personal honoraria from Pierre Fabre and Daiichi Sankyo and has served on an advisory board of Bristol-Myers Squibb. SM has served on an advisory board of GSK. The remaining authors declare no conflict of interest.
: Protocol approval for the METIMMOX trial was obtained from the Regional Committee for Medical and Health Research Ethics of South-East Norway (2017/1850), the Norwegian Medical Agency (17/12752) and the institutional review boards. The trial was conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.
